Evaluation of dosage schedules of mitomycin C (NSC-26980) in children.
D000293:Adolescent; D000740:Anemia / Q000139:chemically induced; D001859:Bone Neoplasms / Q000188:drug therapy; D001932:Brain Neoplasms / Q000188:drug therapy; D002648:Child; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D009455:Neurofibroma / Q000188:drug therapy; D009918:Orbital Neoplasms / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000627:therapeutic use
D008937:Mitomycins; D003609:Dactinomycin; D014750:Vincristine; D003520:Cyclophosphamide